组织芯片检测肝细胞肝癌中ARF6蛋白的表达及临床意义

目的:探讨二磷酸腺苷核糖基化因子6(ADP-ribosylation factor 6,ARF6)在肝细胞肝癌(简称肝癌)组织中的表达及临床意义?方法:收集肝癌手术切除标本150例,以癌旁肝硬化组织作对照,制作组织芯片,用组织芯片技术结合免疫组化法,检测肝癌组织和癌旁肝硬化组织ARF6的表达,探讨ARF6表达与临床病理特征及预后之间的关系?结果:肝癌组织中ARF6的阳性表达率为48.7%(73/150),在癌旁肝硬化组织中ARF6的阳性表达率为8.3%(4/48),两者比较差异有统计学意义(P < 0.05)?肝癌组织中ARF6阳性表达与门静脉癌栓?临床分期?肿瘤直径及甲胎蛋白(AFP)水平相关(P < 0.05)?ARF6表达阴性的肝癌患者在肝切除术后的无瘤中位存活时间为45个月,1?3?5年无瘤生存率分别为(93.22 ± 7.93)%?(58.91 ± 6.18)%?(24.59 ± 6.80)%;ARF6表达阳性患者的无瘤中位存活时间为36个月,1?3?5年无瘤生存率分别为(88.91 ± 3.70)%?(41.61 ± 5.93)%?(19.03 ± 4.94)%?ARF6表达阴性与表达阳性的肝癌患者的无瘤生存时间差异有统计学意义(P = 0.019 1)?结论:肝癌组织中ARF6的表达与预后密切相关,ARF6不仅可作为肝癌预后不良的判断指标,还有望成为一种新的肝癌预后判断的标志物和潜在的治疗靶标?

Expression and clinical significance of ARF6 in hepatocellular carcinoma

Objective:To investigate the expression and clinical significance of ADP-ribosylation factor 6(ARF6) in hepatocellular carcinoma (HCC). Methods:The expression of ARF6 was determined by tissue microarray and immunohistochemistry in 150 cases of HCC and 48 cases of adjacent cirrhosis tissue. Results:The positive expression of ARF6 in HCC and adjacent cirrhosis tissue were 48.7% (73/150) and 8.3% (4/48) respectively(P < 0.05). The positive expression of ARF6 in HCC was closely related to the portal vein invasion,clinical stage,tumor diameter and AFP level. The results also indicated that a high expression level of ARF6 was associated with worse recurrence-free survival. The median recurrence-free survival was substantially reduced among patients with positive ARF6 protein(36 months vs. 45 months,P = 0.019 1). Conclusion:The expression of ARF6 is closely correlated with the clinical prognosis of HCC. It suggests ARF6 may be a potential prognostic biomarker and therapeutic target for HCC.